It's about time to write off high-growth tech stocks, Goldman warned, saying software carries the highest multiples since the tech bubble.Marketsread more
Iran will surpass the internationally agreed levels of its low-enriched uranium levels in 10 days, the country's atomic energy body said Monday.Politicsread more
Boeing said the airline industry will need 44,040 new commercial airplanes by 2038. The market value of those planes would reach $6.8 trillion, up from $6.49 trillion...Airlinesread more
Apple is reportedly building three new iPhones for 2020, including two with 5G. It may also slightly change the screen sizes of the new iPhones.Technologyread more
Sotheby's announces it has signed an agreement to be acquired by BidFair USA, a venture owned by art collector Patrick Drahi.Marketsread more
Overall, extortion by email is growing significantly, according to the FBI's Internet Crime Compliant Center (IC3). Last year, these complaints rose 242% to 51,146 reported...Technologyread more
In a 7-2 ruling, over dissents from Justices Ruth Bader Ginsburg and Neil Gorsuch, the justices affirmed the so-called "dual sovereignty" exception to the Constitution's...Politicsread more
Target's nationwide cash register meltdown over the weekend created more than $16 million in buzz on the internet from news reports and other social media mentions, according...Retailread more
The chipmaker crush could persist and investors should be selective, but Nvidia looks like a clear buy, one market watcher says.Trading Nationread more
The top court scrapped a ruling from the Oregon Court of Appeals in favor of the same-sex couple. The owners of the bakery, which refused the make the cake due to religious...Politicsread more
Boeing reached a deal with British Airways to provide parts for some of its plane's made by rival manufacturer Airbus, part of Boeing's push to grow its services business.Airlinesread more
"These stocks ... used to be safety-first situations. No longer," he told investors. "These names are bouncing today, but the next time the market gets slammed, you don't want to rely on a broken drug stock — or food stock, for that matter — to protect your portfolio."
The toxicity has spread to the likes of Allergan, the "Mad Money" host said. In an unusual move, shares of the Botox maker plummeted after the company reported earnings above Wall Street estimates and raised its guidance on Tuesday.
"Allergan does have two huge ... drugs in its pipeline, an acute migraine medication and a treatment for depression, but neither, I think, is going to be enough to help [in] 2019," Cramer said. "If you bought Allergan['s stock] right after its supposedly good quarter when it was jumping up, you lost more than 20 points in the blink of an eye."
"If this is how it behaves after a beat and raise, I say no thank you," he added.
Also in the house of pain is the stock of drugmaker Gilead, a pioneer in hepatitis treatments. The stock has "been a falling knife for ages" as the company waffled on how to further monetize its leading medicines, Cramer said.
Gilead's Hepatitic C cure "worked too well — when you cure a disease, you start running out of customers," he said. "Now Gilead's introducing its own generic version of this drug 10 years before it loses patent protection, and while that's a very noble gesture, it sure seems like a terrible business strategy. While the stock bounced today, I can't see it turning around long term."
"The drug stocks ... have long been viewed as a bastion of reliability, but lately a number of big pharma names have just been annihilated and that's highly unusual," he said. "Safety's last with these guys now. These stocks are something like Donna Summer, 'cause when they're bad, they're so, so bad."